

Table 1 Baseline characteristics of participating patients infected with HCV genotype 1b

Total number	239
Age (years) ^a	57 (21–78)
Gender (male/female)	142/97
Body mass index (kg/m ²) ^a	23.3 (15.3–31.0)
Previous interferon therapy (no/yes)	167/72
Histology at biopsy	
Grade of inflammation	
A0/1/2/3	3/65/102/10
Stage of fibrosis	
F0/1/2/3/4	4/73/57/37/9
Hemoglobin (g/dl) ^b	14.3 ± 1.3
ALT (IU/L) ^b	86 ± 67
Platelet count (× 10 ³ /μl) ^b	160 ± 58
LDL cholesterol (mg/dl) ^b	74 ± 19
Serum HCV-RNA level (Log(IU/ml)) ^{b, c}	6.1 ± 0.6
Type of mutations in the core (dM/non dM)	30/166
Type of mutations in the core (dW/non dW)	65/131
Type of ISDR sequence (0/1/2/3/4 or more)	126/45/11/5/18

HCV hepatitis C virus, LDL low density lipoprotein, ALT alanine transaminase, ISDR interferon sensitivity determining region in NS5A 2209–2248, dM double mutant: dual substitutions at amino acids 70 and 91, non dM non-double mutant: wild type or substitution at either amino acid 70 or 91, dW double wild: wild type at amino acids 70 and 91, non dW non-double wild: dual or substitution at either amino acid 70 or 91

^a Median (range) values are shown

^b Data are mean ± SD

^c Data are shown as Log(IU/ml)

reduction. The SVR rates of patients who received a total cumulative treatment dose of PEG-IFN of more than 80% were almost twice as high as the rates of patients who received less than 80% (56%, 26%, and 9% with >80%, 60%–80% and <60% of the PEG-IFN dose, $P < 0.001$). The SVR rates did not decrease with RBV reduction, as long as the cumulative treatment dose of RBV was more than 60%, but when the RBV reduction fell below 60%, the SVR rates were significantly lower (56%, 38%, and 10% with >80%, 60%–80%, and <60% of the RBV dose, $P < 0.001$).

Factors associated with sustained virological response

Seven parameters that influenced the SVR rate were identified by univariate analysis, including stage of fibrosis at liver biopsy, hemoglobin, platelet count, serum HCV RNA level, the type of ISDR sequence, and adherence to PEG-IFN plus RBV (Table 3). On the other hand, the SVR rate was not related to gender ($P = 0.07$), age or BMI. The amino acid substitution pattern was not significant in the overall analysis, but female patients with dual substitutions

Table 2 Sustained response rates to treatment according to drug adherence

Characteristic	Number/total number (%)
Overall	
End of treatment	172/239 (72)
End of follow up	98/239 (41)
PEG-interferon- α 2b adherence	
End of treatment	
>80%	131/154 (85)
60–80%	19/27 (70)
<60%	22/58 (38)
End of follow up	
>80%	86/154 (56)
60–80%	7/27 (26)
<60%	5/58 (9)
Ribavirin adherence	
End of treatment	
>80%	113/134 (84)
60–80%	37/46 (80)
<60%	22/59 (37)
End of follow up	
>80%	74/133 (56)
60–80%	18/47 (38)
<60%	6/59 (10)

PEG pegylated

at amino acids 70 and 91 had a low tendency to achieve SVR. As shown in Table 4, gender differences existed in the mutations in ISDR and core regions based on therapeutic responses. Because there were rather fewer female than male patients, the type of ISDR sequence did not significantly influence the SVR in females. We also analyzed types of mutations in the core, and the amino acid substitution pattern was not significant in the male patients, but female patients with dual substitutions at amino acids 70 and 91 had a low tendency to achieve an SVR, as mentioned above. We also compared results between treatment-naïve patients and those who had failed previous IFN therapy (Table 5). As there were some differences in stage of fibrosis, platelet count, grade of inflammation, and gender in univariate analysis, treatment was comparably effective in both groups.

Finally we performed multivariate analysis in subjects with good drug adherence (Table 6), which identified only one parameter that influenced the SVR rate independently by variable selection: the number of mutations in the ISDR sequence (two or more: odds ratio [OR] = 5.181, $P < 0.05$). This regression model was always obtained regardless of the variable selection method used, including conditional parameter estimation, Wald statistic, and

Table 3 Clinical and virological characteristics of 239 patients treated with PEG-IFN plus RBV therapy, based on therapeutic response

	SVR (<i>n</i> = 98)	Non-SVR (<i>n</i> = 141)	<i>P</i> value
Age (years) ^a	56 (27–69)	58 (23–72)	NS
Gender (male/female)	65/33	77/64	0.070
Previous interferon therapy (no/yes)	68/30	99/42	NS
Grade of inflammation (A0–1/2–3)	31/50	37/62	NS
Stage of fibrosis (F0–2/3–4)	68/13	67/33	0.009
Body mass index (kg/m ²) ^a	23.3 (15.5–28.1)	23.3 (15.3–31.0)	NS
Pretreatment Hemoglobin (g/dl) ^b	14.6 ± 1.1	14.0 ± 1.4	<0.001
Pretreatment ALT (IU/ml) ^b	87 ± 68	86 ± 67	NS
Pretreatment platelet count (×10 ³ /μl) ^b	178 ± 63	148 ± 51	<0.001
Pretreatment LDL cholesterol (mg/dl) ^b	78 ± 21	72 ± 18	NS
Pretreatment serum HCV-RNA level (Log(IU/ml)) ^{b, c}	5.9 ± 0.7	6.2 ± 0.4	<0.001
No. of mutations in the ISDR (0–1/2 or more)	66/23	105/11	0.002
Type of mutations in the core (dM/non dM)	9/76	21/90	NS
Type of mutations in the core (dW/non dW)	31/54	34/77	NS
PEG-interferon adherence (>80/60–80/<60%)	85/7/6	68/20/53	<0.001
Ribavirin adherence (>80/60–80/<60%)	72/19/7	60/28/53	<0.001

IFN interferon, RBV ribavirin, SVR sustained virological response, NS not significant, ALT alanine transaminase, ISDR interferon sensitivity determining region in NS5A_{2209–2248}, core substitution of amino acids 70 and 91, dM double mutant: dual substitutions at amino acids 70 and 91, non dM non-double mutant: wild type or substitution at either amino acid 70 or 91, dW double wild: wild type at amino acids 70 and 91, non dW non-double wild: dual or substitution at either amino acid 70 or 91

^a Median (range) values are shown

^b Data are mean ± SD

^c Data are shown as Log(IU/ml)

Table 4 Mutations in the ISDR and core regions analyzed separately for gender based on therapeutic response

	SVR (<i>n</i> = 98)	Non-SVR (<i>n</i> = 141)	<i>P</i> value
No. of mutations in the ISDR (0–1/2 or more)			
Male	36/21	56/8	0.002
Female	30/2	49/3	NS
Type of mutations in the core (dM/non dM)			
Male	8/46	11/48	NS
Female	1/30	10/42	0.026
Type of mutations in the core (dW/non dW)			
Male	18/36	16/43	NS
Female	13/18	18/34	NS

likelihood ratio statistic in combination with forward or backward variable selection methods.

Comparison of SVR rates according to the number of mutations in the ISDR sequence

We analyzed first the percentage of patients with more than two mutations in the ISDR among 762 patients who received IFN therapy between December 2000 and April

2008 at Tokyo Medical and Dental University Hospital and associated hospitals. The percentage of patients with more than two mutations in the ISDR was between about 20% and 30% for all ages (Fig. 1a).

Secondly, we analyzed responses to PEG-IFN plus RBV treatment and serum levels of HCV RNA in relation to the number of mutations in the ISDR. In Fig. 1b, patients with SVR are indicated by open circles and those with non-SVR, by closed circles. Although the rate of SVR tended to be higher in patients with increasing numbers of mutations in the ISDR, 5 patients with more than two mutations in the ISDR who experienced drug discontinuation and dose reduction resulted in non-SVR.

We confirmed changes over time in VR rates in patients treated with PEG-IFN plus RBV (Fig. 1c). Patients with more than two mutations in the ISDR are indicated in the figure by open circles and those with none or one mutation in the ISDR, by closed circles. The VR rates tended to be high early in the treatment in patients with more than two mutations in the ISDR.

Finally we compared the PEG-IFN plus RBV treatment efficacy in two groups, divided based on ISDR mutations. Patients with more than two mutations in the ISDR had a significantly higher tendency to achieve SVR in both ITT and per-protocol (PP) analyses (*P* < 0.01) (Fig. 1d), and

Table 5 Clinical and virological characteristics of 239 patients treated with PEG-IFN plus RBV therapy, based on previous interferon therapy

Previous interferon therapy	No (n = 167)	Yes (n = 72)	P value
Sustained response rates	68/167 (41)	30/72 (42)	NS
Age (<65/≥65)	127/40	57/15	NS
Gender (male/female)	93/74	49/23	0.074
Grade of inflammation (A0–1/2–3)	55/72	13/40	0.018
Stage of fibrosis (F0–2/3–4)	103/24	32/21	0.003
Pretreatment hemoglobin (<14.5/≥14.5)	93/74	41/31	NS
Pretreatment platelet count (<160/≥160 × 10 ³)	84/83	50/22	0.006
Pretreatment Serum HCV RNA level ^a (<6/≥6)	54/112	25/46	NS
No. of mutations in the ISDR (0–1/2 or more)	116/22	55/12	NS
PEG-interferon adherence (>80/60–80/<60%)	110/18/39	43/9/20	NS
Ribavirin adherence (>80/60–80/<60%)	97/30/40	35/17/20	NS

^a Data are shown as Log(IU/ml)

Table 6 Multivariate analysis for the clinical and virological factors related to sustained response to PEG-IFN plus RBV therapy in 104 patients who were not intolerant to PEG-IFN plus RBV therapy

Factor	Category	Odds ratio (95% CI)	P value
(a) Five-factor model			
Number of mutations in the ISDR	0 or 1	1	0.063
	2 or more	4.486 (0.922–21.74)	
Pretreatment Hemoglobin (g/dl)		1.250 (0.853–1.833)	NS
Pretreatment Serum HCV RNA level ^a		0.510 (0.224–1.159)	NS
Stage of fibrosis	F 0/1/2	1	NS
	F 3/4	0.460 (0.153–1.382)	
Pretreatment Platelet count (× 10 ³ /μl)		1.022 (0.949–1.101)	
(b) Step-wise variable selection			
Number of mutations in the ISDR	0 or 1	1	0.034
	2 or more	5.181 (1.129–23.81)	

CI confidence interval, ALT alanine transaminase, ISDR interferon sensitivity determining region in NS5A 2209–2248

^a Data are shown as Log(IU/ml)

the SVR rates of the patients with good drug adherence was 80%.

Side effects

Side effects leading to treatment discontinuation occurred in 53 patients (22%). Overall, 109 patients (46%) required reduction of the dose of one or both drugs during the treatment regimens (23% required PEG-IFN reduction and 35% required RBV reduction). The most common events leading to drug withdrawal were general fatigue and appetite loss ($n = 15$), hematologic abnormalities ($n = 6$), dermatological symptoms ($n = 5$), retinopathy ($n = 5$), neuro-psychiatric events ($n = 4$), and interstitial pneumonia, including severe cough ($n = 4$).

Discussion

Although the relationship between ISDR mutations and the clinical efficacy of IFN has been conflicting in Western countries [18–24], our results support previous studies reporting a close correlation between the number of mutations in the ISDR and IFN efficacy in patients with chronic HCV-1b infection [11–13]. Because most patients with 4 or more mutations in the ISDR (hereafter classified as the mutant type) experienced SVR with conventional IFN monotherapy, we reported previously that the number of amino acid substitutions in the ISDR was an independent predictor of the response to IFN therapy [12]. In the present study, we demonstrate that ISDR mutations are the most effective predictors of treatment outcome of 48-week




Fig. 1 a The percentages of patients with more than two mutations in the interferon sensitivity determining region in NS5A_{2209–2248} (ISDR), according to age (horizontal axis) among 762 patients who received interferon (IFN) therapy between December 2000 and April 2008 at Tokyo Medical and Dental University Hospital and associated hospitals. b Responses to pegylated (PEG)-IFN plus ribavirin (RBV) treatment and serum levels of hepatitis C virus (HCV) RNA in relation to the number of mutations in the ISDR. Patients with sustained virological response (SVR) are indicated by open circles and those with non-SVR by closed circles. c Changes over time in VR rates in patients treated with PEG-IFN plus RBV. Patients with more than two mutations in the ISDR are indicated by open circles and those with no or one mutation in the ISDR by closed circles, W weeks. d PEG-IFN plus RBV treatment efficacy divided into two groups based on ISDR mutations. End-of-treatment response (ETR) and SVR are shown in both intention-to-treat (ITT) analysis (left) and per-protocol (PP) analysis (right)

regard to age, there was no relation to SVR in overall analysis with continuous variables, but younger patients, aged less than 65 years, had a higher rate of response than those aged more than 65 years ($P < 0.05$, data not shown). Actually there are some reports suggesting the relationship of age and SVR [25, 26]. Finally, in regard to previous IFN therapy, as shown in Table 5, treatment was comparably effective in both groups; previous IFN therapy did not affect the SVR rate. The reasons for equivalent response rates in subjects with prior IFN history, which was not expected, are unclear. In our study, the group with prior IFN history had more advanced liver fibrosis and a low platelet count, and stage of fibrosis was one of the factors extracted by univariate analysis as a useful pretreatment marker predicting SVR. We also analyzed the other three parameters extracted by univariate analysis. Although there was no difference in pretreatment hemoglobin, or number of ISDR mutations, the group with prior IFN history tended to have a low serum HCV-RNA level. Further, the group with prior IFN history had a high proportion of male patients. Although the SVR rate was not related to gender, male subjects had a higher tendency to achieve SVR than female subjects.

In our present study, the SVR rate was not related to core mutations. As described in previous reports [17, 27, 28], amino acid substitutions in the core region are regarded as predictors of response to PEG-IFN plus RBV therapy in Japanese patients infected with HCV genotype 1b. In the present study, the SVR rate was not related to the pattern of amino acid substitution in the overall analysis. The reasons for these discrepant results are unclear, but females with dual substitutions at amino acids 70 and 91 had a lower tendency to achieve SVR. Further studies are necessary to clarify the mechanism of action for amino acid substitutions in the core region of HCV.

Recent studies suggest that the mutations in the ISDR are associated with response to combination therapy with IFN and RBV [29–32]. Most recently, it has been reported

PEG-IFN plus RBV therapy in patients with HCV genotype 1b infection.

In the present study, the SVR rate was not related to gender, age, or previous IFN therapy by univariate analysis. First of all, in regard to gender ($P = 0.07$), as male patients had a higher tendency to achieve SVR than female patients, further validation in larger-scale studies is required to clarify the significance of gender. Secondly, in

that amino acid substitutions in the core and mutations in the ISDR are predictive of virological response to the combination therapy in patients with HCV genotype 1b and a high viral load [28]. There are some reports suggesting that the mutations in the ISDR may not serve as a predictor for treatment outcome [33, 34], but as the numbers of subjects in these studies were around 30, a number which is not sufficient to evaluate the results, this factor may explain these discrepant results.

The mechanisms of IFN sensitivity in relation to the sequence of the HCV NS5A_{2209–2248} region are not clear. However the “mutant-type” ISDR correlates with a low viral load, as reported previously [12, 35, 36]; most patients in the present study with two or more mutations in the ISDR had high levels of virus. Furthermore, stepwise multiple logistic regression analysis of the factors, including substitution of the ISDR and the viral load, revealed that both of them were independent predictive variables of SVR, and the odds ratio of the number of mutations in the ISDR was the highest in the pretreatment factors associated with SVR by multivariate analysis. The precise mechanism involved must be elucidated in further *in vitro* studies.

There have been several reports that suggest biological roles of the ISDR in the response to IFN and in HCV infection. Double-stranded RNA-dependent protein kinase (PKR) is a critical component of the cellular antiviral responses induced by IFN. Gale et al. [37, 38] have reported that mutations within the PKR-binding region of NS5A, including ISDR, can disrupt the NS5A–PKR interaction, possibly rendering HCV sensitive to the antiviral effects of IFN. Toll-like receptor (TLR) has also been reported to play various roles in many viral infections, and it has been reported that NS5A bound MyD88, a major adaptor molecule of TLR-mediated signaling, and inhibited the TLR–MyD88 signaling pathway by a direct interaction with the death domain of MyD88 through the ISDR [39]. Furthermore, it has been reported that the lipid droplet is an important organelle for HCV production, and NS5A is a key protein that recruits replication complexes to lipid droplets for the production of infectious viral particles [40]. While the mechanism of action of the ISDR in the response to IFN or viral replication remains to be proven, these findings suggest new aspects of HCV infections.

In our previous report [12], patients with 4 or more mutations in the ISDR experienced SVR with conventional IFN monotherapy, but in more effective therapy with PEG-IFN plus RBV combination therapy, the number of mutations as a predictor of SVR decreased from 4 to 2. Watanabe et al. [41] have also reported that the number and position of mutations in the ISDR correlated with IFN efficacy in HCV-1b infection. Moreover, it has been reported that patients with viruses mutated at

positions 2209, 2216, or 2227 more frequently experienced SVR than did those without these mutations. Another group has also reported regarding statistical analysis, using a database of 675 individual ISDR sequences in HCV-NS5A and the IFN response [42]. They have shown that IFN-sensitive viruses contain a larger and more diverse collection of substitutions than IFN-resistant viruses. While it remains unknown how the numbers of mutations are involved in the biological role of ISDR, or which sites of mutation and changes of amino acid are also important for the response to IFN-based treatment, it is thought that the functional importance of numbers or sites of mutations can be explained in terms of interaction between NS5A and some target molecules such as PKR, MyD88, and lipid droplets.

In vitro studies have shown that the introduction of NS5A mutations enables an HCV replicon to replicate efficiently [10, 43, 44]. In our previous report, site-specific mutation of the ISDR also modulated HCV replication [45]. The ISDR was identified originally as the site that determines the sensitivity of HCV to IFN [12]. This indicates that the ISDR mutations are not lethal *in vivo*. Furthermore, mutations in the ISDR are closely associated clinically with decreased serum HCV RNA levels [42], whereas ISDR mutations in the HCV replicon enhance replication. While the explanation for this paradox has not become clear, a big difference between the environment of cultured cells and that in the human liver is thought contribute to this phenomenon.

We found that the percentage of patients with more than two mutations in the ISDR was between 20% and 30% for all ages; thus, around one-fifth of patients are thought likely to experience SVR. Indeed, the SVR rate among patients with two or more mutations in the ISDR sequence was 68% (ITT) and 80% (PP) compared to 39% (ITT) and 50% (PP) among those patients with no or one mutation in the present study. Furthermore, predictive factors such as serum HCV RNA level, stage of fibrosis, and hemoglobin also aid in the assessments of treatment, and we can use these parameters to develop a treatment strategy.

Several prospective randomized trials have shown that 72-week extended therapy improves SVR by 7.5%–12% in late viral responders [46, 47]. One cohort study showed that 72-week treatment for late viral responders achieved an even higher SVR, of 67.1%, which was 21% higher than the SVR achieved with 48-week treatment [48]. These reports demonstrate that tailoring of treatment duration by on-treatment viral response can further improve the outcomes of antiviral therapy. In our 48-week based treatment, 90% of patients with more than 2 ISDR mutations cleared the virus within 12 weeks of treatment (early viral response; EVR) and consequently achieved 30% higher SVR than those with 1 or no ISDR mutation. These results

suggest that ISDR mutations will remain a significant predictor of good response to IFN therapies, including 72-week extension.

In conclusion, ISDR mutations are the most effective predictors of treatment outcomes in multivariate analysis. The number of mutations in the ISDR sequence of HCV-1b (≥ 2) is the most effective parameter which will facilitate further the selection of patients with a high likelihood of response to PEG-IFN plus RBV treatment.

Acknowledgments This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology-Japan; the Japan Society for the Promotion of Science; the Ministry of Health, Labour and Welfare-Japan; the Japan Health Sciences Foundation; the Miyakawa Memorial Research Foundation; and the National Institute of Biomedical Innovation. The following hospitals participated in the Ochanomizu-Liver Conference Study Group: Oume City General Hospital, Kashiwa City Hospital, Kudanzaka Hospital, Showa General Hospital, Shuwa General Hospital, Soka Municipal Hospital, Tama-Nambu Chiiki Hospital, Tuchiura Kyodo General Hospital, Tokyo Kyosai Hospital, Tokyo Metropolitan Ohtsuka Hospital, Tokyo Metropolitan Fuchu Hospital, Tokyo Metropolitan Bokutoh Hospital, Toride Kyodo General Hospital, Nakano General Hospital, Hokushin General Hospital, Mishima Social Insurance Hospital, Musashino Red Cross Hospital, Yokosuka Kyosai Hospital, Yokohama City Minato Red Cross Hospital.

References

- Major ME, Feinstone SM. The molecular virology of hepatitis C. *Hepatology*. 1997;25:1527–38.
- Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science*. 1989;244:359–62.
- Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. *Lancet*. 1991;337:1058–61.
- Dibisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, et al. A pilot-study of ribavirin therapy for chronic hepatitis-C. *Hepatology*. 1992;16:649–54.
- Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. *J Hepatol*. 1996;25:591–8.
- Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O, et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. *Lancet*. 1998;351:83–7.
- Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *Lancet*. 1998;352:1426–32.
- McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med*. 1998;339:1485–92.
- Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. *Clin Pharmacol Ther*. 2000;68:556–67.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marionos G, Goncalves FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*. 2002;347:975–82.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. *J Clin Invest*. 1995;96:224–30.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med*. 1996;334:77–81.
- Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. *Hepatology*. 1997;25:750–3.
- Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. *J Gen Virol*. 1994;75:1361–9.
- Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular-cloning of the human hepatitis-C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA*. 1990;87:9524–8.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology*. 2005;48:372–80.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. *Hepatology*. 2007;46:1357–64.
- Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon Alfa. *Hepatology*. 1997;25:740–4.
- Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, et al. Mutations of hepatitis C virus 1b NS5A 2209–2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. *J Hepatol*. 1997;27:72–7.
- Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. *Gastroenterology*. 1997;113:567–72.
- Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. *J Med Virol*. 1997;53:118–26.
- Squadrito G, Orlando ME, Cacciola I, Rumi MG, Artini M, Picciotto A, et al. Long-term response to interferon alpha is unrelated to “interferon sensitivity determining region” variability in patients with chronic hepatitis C virus-1b infection. *J Hepatol*. 1999;30:1023–7.
- Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. *J Med Virol*. 1999;58:353–8.
- Sarrazin C, Berg T, Lee JH, Teuber G, Dietrich CF, Roth WK, et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. *J Hepatol*. 1999;30:1004–13.
- Honda T, Katano Y, Urano F, Murayama M, Hayashi K, Ishigami M, et al. Efficacy of ribavirin plus interferon-alpha in patients aged ≥ 60 years with chronic hepatitis C. *J Gastroenterol Hepatol*. 2007;22:989–95.

26. Hung CH, Chen CH, Lee CM, Wu CM, Hu TH, Wang JH, et al. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. *J Viral Hepatitis*. 2008;15:58–65.
27. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. *J Med Virol*. 2006;78:83–90.
28. Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. *J Med Virol*. 2009;81:640–9.
29. Yen YH, Hun CH, Hu TH, Chen CH, Wu CM, Vvang JH, et al. Mutations in the interferon sensitivity-determining region (non-structural 5A amino acid 2209–2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. *Aliment Pharmacol Ther*. 2008;27:72–9.
30. Hung CH, Lee CM, Lu SN, Lee JF, Wang JH, Tung HD, et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. *J Viral Hepatitis*. 2003;10:87–94.
31. Murayama M, Katano Y, Nakano I, Ishigami M, Hayashi K, Honda T, et al. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b. *J Med Virol*. 2007;79:35–40.
32. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. *Hepatology*. 2008;48:1753–60.
33. Murphy MD, Rosen HR, Marousek GI, Chou SW. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. *Dig Dis Sci*. 2002;47:1195–205.
34. Yang SS, Lai MY, Chen DS, Chen GH, Kao JH. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. *Liver Int*. 2003;23:426–33.
35. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. *Hepatology*. 1997;25:745–9.
36. Watanabe H, Nagayama K, Enomoto N, Itakura J, Tanabe Y, Hamano K, et al. Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection. *Virology*. 2003;311:376–83.
37. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. *Virology*. 1997;230:217–27.
38. Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. *Mol Cell Biol*. 1998;18:5208–18.
39. Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen XY, Tagawa S, et al. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor–MyD88-dependent signaling pathway in macrophage cell lines. *J Virol*. 2007;81:8953–66.
40. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for hepatitis C virus production. *Nat Cell Biol*. 2007;9:1089–97.
41. Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, et al. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. *J Infect Dis*. 2001;183:1195–203.
42. Witherell GW, Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. *J Med Virol*. 2001;63:8–16.
43. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. *Science*. 2000;290:1972–4.
44. Maekawa S, Enomoto N, Sakamoto N, Kurosaki M, Ueda E, Kohashi T, et al. Introduction of NS5A mutations enables sub-genomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells. *J Viral Hepatitis*. 2004;11:394–403.
45. Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H, Tanabe Y, et al. Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. *J Viral Hepatitis*. 2006;13:582–90.
46. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology*. 2006;130:1086–97.
47. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C types 1 and 4 patients with slow virologic response. *Gastroenterology* 2009 [Epub ahead of print].
48. Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, et al. Prolonged treatment with pegylated interferon a 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. *Hepatol Res* 2009 [Epub ahead of print].

Original Article

A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis

Masayuki Kurosaki,¹ Kotaro Matsunaga,² Itsuko Hirayama,¹ Tomohiro Tanaka,¹ Mitsuaki Sato,¹ Yutaka Yasui,¹ Nobuharu Tamaki,¹ Takanori Hosokawa,¹ Ken Ueda,¹ Kaoru Tsuchiya,¹ Hiroyuki Nakanishi,¹ Hiroki Ikeda,¹ Jun Itakura,¹ Yuka Takahashi,¹ Yasuhiro Asahina,¹ Megumu Higaki,⁴ Nobuyuki Enomoto³ and Namiki Izumi¹

¹Division of Gastroenterology and Hepatology and ²Division of Pathology, Musashino Red Cross Hospital, Tokyo, ³First Department of Internal Medicine, University of Yamanashi, Yamanashi, and ⁴Department of Medical Science, Jikei Medical University, Tokyo, Japan

Aim: Early disappearance of serum hepatitis C virus (HCV) RNA is the prerequisite for achieving sustained virological response (SVR) in peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C. This study aimed to develop a decision tree model for the pre-treatment prediction of response.

Methods: Genotype 1b chronic hepatitis C treated with PEG-IFN alpha-2b and RBV were studied. Predictive factors of rapid or complete early virological response (RVR/cEVR) were explored in 400 consecutive patients using a recursive partitioning analysis, referred to as classification and regression tree (CART) and validated.

Results: CART analysis identified hepatic steatosis (<30%) as the first predictor of response followed by low-density-lipoprotein cholesterol (LDL-C) (≥ 100 mg/dL), age (<50 and <60 years), blood sugar (<120 mg/dL), and gamma-glutamyltransferase (GGT) (<40 IU/L) and built decision tree

model. The model consisted of seven groups with variable response rates from low (15%) to high (77%). The reproducibility of the model was confirmed by the independent validation group ($r^2 = 0.987$). When reconstructed into three groups, the rate of RVR/cEVR was 16% for low probability group, 46% for intermediate probability group and 75% for high probability group.

Conclusions: A decision tree model that includes hepatic steatosis, LDL-C, age, blood sugar, and GGT may be useful for the prediction of response before PEG-IFN plus RBV therapy, and has the potential to support clinical decisions in selecting patients for therapy and may provide a rationale for treating metabolic factors to improve the efficacy of antiviral therapy.

Key words: data mining, decision tree, HCV, low-density-lipoprotein cholesterol, steatosis

INTRODUCTION

COMBINATION THERAPY WITH pegylated interferon (PEG-IFN) and ribavirin (RBV) is now recognized as a standard treatment for patients with chronic hepatitis C.¹ However, the rate of sustained virological response (SVR) to 48 weeks of PEG-IFN RBV combina-

tion therapy is only 50% in patients with hepatitis C virus (HCV) genotype 1b and high HCV RNA titer, so called difficult to treat chronic hepatitis C patients.^{2,3} Within this difficult to treat group, the response to treatment sometimes can be highly heterogeneous for cases which are apparently equivalent in HCV RNA titer, making the prediction of response before treatment a difficult task. It has been suggested that early virological response (EVR), defined as either undetectable HCV RNA or a 2 log drop in HCV RNA at week 12, is a reliable means to predict SVR.^{2,4} More recently, it has been suggested that patients with a rapid virological response (RVR: undetectable HCV RNA at week 4) and a complete EVR (cEVR: undetectable HCV RNA at week 12)

Correspondence: Dr Namiki Izumi, Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan. Email: nizumi@musashino.jrc.or.jp
Received 26 May 2009; revision 25 August 2009; accepted 26 August 2009.

achieve high SVR rates, while patients with a partial eVR (pEVR: 2 log drop in HCV RNA but still detectable at week 12) have lower rates of SVR.⁵ Since PEG-IFN RBV combination therapy is costly and accompanied by potential adverse effects, the ability to predict the possibility of RVR or cEVR before therapy and identifying curable patients may significantly influence the selection of patients for therapy. Moreover, identification of baseline predictors of poor response is particularly important to establish a rationale for identifying therapeutic targets to improve the efficacy of antiviral therapy.

Data mining is a method of predictive analysis which explores tremendous volumes of data to discover hidden patterns and relationships in highly complex datasets and enables the development of predictive models. The classification and regression tree (CART) analysis is a core component of the decision tree tool for data mining and predictive modeling,⁶ is deployed to decision makers in various fields of business, and currently is being used in the area of biomedicine.^{7–13} The results of CART analysis are presented as a decision tree, which is intuitive and facilitates the allocation of patients into subgroups by following the flow-chart form.¹⁴ CART has been shown to be competitive with other traditional statistical techniques such as logistic regression analysis.¹⁵

In the present study, we used the CART analysis to explore baseline predictors of response to PEG-IFN plus RBV therapy among clinical, biochemical, virological and histological pretreatment variables and to define a pre-treatment algorithm to discriminate chronic hepatitis C patients who are likely to respond to PEG-IFN plus RBV therapy.

MATERIALS AND METHODS

Patients

A TOTAL OF 419 chronic hepatitis C patients were treated with PEG-IFN alpha-2b and RBV at Musashino Red Cross Hospital between December 2001 and December 2007. Among them, 400 patients who fulfilled the following inclusion criteria were enrolled in the present study. (i) infection by genotype 1b (ii) HCV RNA higher than 100 IU/mL by quantitative PCR (Cobas Amplicor HCV Monitor, Roche Diagnostic systems, CA) which is usually used for the definition of high viral load in Japan (iii) lack of co-infection with hepatitis B virus or human immunodeficiency virus (iv) lack of other causes of liver disease such as autoimmune hepatitis, primary biliary cirrhosis, or alcohol intake of more than 20 g per day, and (v) having completed at

least 12 weeks of therapy with an early virological response that could be evaluated. Patients received PEG-IFN alpha-2b (1.5 microgram/kg) subcutaneously every week and were administered a weight adjusted dose of RBV (600 mg for <60 kg, 800 mg for 60–80 kg, and 1000 mg for >80 kg) which is the recommended dosage in Japan. Data from two third of patients (269 patients) were used for the model building set and the remaining one third of patients (131 patients) were used as a validation set. Consent in writing was obtained from each patient and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review committee.

Laboratory tests

Blood samples were obtained before therapy, and at least once every month during therapy and analyzed for hematologic tests, blood chemistries, and HCV RNA. In the present study, RVR and cEVR was defined as undetectable HCV RNA by qualitative PCR with a lower detection limit of 50 IU/mL (Amplicor, Roche Diagnostic systems, CA) at week 4 and 12, respectively. SVR was defined as undetectable HCV RNA at week 24 after the completion of therapy.

Histological examination

For all patients, liver biopsy specimens were obtained before therapy and were evaluated independently by three pathologists who were blinded to the clinical details. If there was a disagreement, the scores assigned by the majority of pathologists were used for the analysis. Fibrosis and activity were scored according to the METAVIR scoring system.¹⁶ Fibrosis was staged on a scale of 0–4: F0 (no fibrosis), F1 (mild fibrosis: portal fibrosis without septa), F2 (moderate fibrosis: few septa), F3 (severe fibrosis: numerous septa without cirrhosis) and F4 (cirrhosis). Activity of necroinflammation was graded on a scale of 0–3: A0 (no activity), A1 (mild activity), A2 (moderate activity) and A3 (severe activity). Percentage of steatosis was quantified by determining the average proportion of hepatocytes affected by steatosis and graded on a scale of 0–3: grade 0 (no steatosis), grade 1 (0–9%), grade 2 (10–29%), and grade 3 (over 30%) as we reported previously.¹⁷

Database for analysis

A pretreatment database of 72 variables was created containing histological findings (grade of fibrosis, activity, and steatosis), laboratory tests including the quantity of HCV RNA by Cobas Amplicor, and clinical information (age, gender, body weight, and body mass index).

The baseline characteristics and test results are listed in Table 1. The overall rate of RVR/cEVR was 43% in the model building set and 48% in the validation set. There were no significant differences in the clinical backgrounds between these two groups. Hepatitis C viral mutations, such as mutations in interferon-sensitivity determining region or core amino acid residues 70 and 91, were not included in the present analysis. The dataset of laboratory tests was based on the digitized records in this hospital. Continuous data was split into categorized data by increment of 10; For example, age was categorized into <30, 30–39, 40–49, 50–59, 60–69, and ≥70.

Statistical analysis

Based on this database, the recursive partitioning analysis algorithm referred to as CART was implemented to define meaningful subgroups of patients with respect to the possibility of achieving RVR/cEVR. The CART belongs to a family of nonparametric regression methods based on binary recursive partitioning of data. The software automatically explore the data to search for optimal split variables, builds a decision tree structure and finally classifies all subjects into particular subgroups that are homogeneous with respect to the outcome of interest.¹⁸ During the CART analysis, first, the entire study population, and thereafter, all newly defined subgroups, were investigated at every step of the analysis to determine which variable at what cut-off point yielded the most significant division into two prognostic subgroups that were as homogeneous as possible with respect to estimates of RVR/cEVR possibilities. This algorithm uses the impurity function (Gini criterion function) for splitting.¹⁹ A restriction was imposed on the tree construction such that terminal subgroups resulting from any given split must have at least 20 patients. The CART procedure stopped when either no additional significant variable was detected or when the sample size was below 20. The resulting final subgroups were most homogeneous with respect to the probability of achieving RVR/cEVR. For this analysis, data mining software Clementine version 12.0 (SPSS Inc, Chicago, IL) was utilized. SPSS 15.0 (SPSS Inc, Chicago, IL) was used for logistic regression analysis.

RESULTS

Factors associated with RVR/cEVR by standard statistical analysis

WE FIRST ANALYZED 72 variables by univariate and multivariate logistic regression analysis to find factors associated with RVR/cEVR (Table 2).

Patients with RVR/cEVR were significantly younger than those without. Among histological findings, grade of steatosis and stage of fibrosis was significantly lower in RVR/cEVR. Among hematologic tests, hemoglobin and hematocrit was significantly higher in RVR/cEVR. Among blood chemistry tests, creatinine and low-density lipoprotein cholesterol (LDL-C) was significantly higher and gamma-glutamyltransferase (GGT), low-density-lipoprotein cholesterol (LDL-C), and blood sugar were significantly lower in RVR/cEVR. The level of HCV RNA was significantly lower in RVR/cEVR. There were no significant differences in other tests.

Multivariate logistic regression analysis was performed on age, fibrosis stage, steatosis, HCV RNA, creatinine, hemoglobin, GGT, LDL-C, and blood sugar; hematocrit was not included since it is closely associated with hemoglobin. On multivariate analysis, age, grade of steatosis, level of HCV RNA, creatinine, hemoglobin, GGT, and LDL-cholesterol remained significant whereas stage of fibrosis, hemoglobin and blood sugar were not.

The CART analysis

The CART analysis was carried out on the model building set of 269 patients using the same variables as logistic regression analysis. Figure 1 shows the resulting decision tree. The CART analysis automatically selected five predictive variables to produce a total of seven subgroups of patients. The grade of steatosis was selected as the variable of initial split with an optimal cut-off of 30%. The possibility of achieving RVR/cEVR was only 18% for patients with hepatic steatosis of 30% or more compared to 47% for patients with hepatic steatosis of less than 30%. Among patients with hepatic steatosis of less than 30%, the level of serum LDL-C, with an optimal cut-off of 100 mg/dL, was selected as the variable of second split. Patients with higher LDL-C level had the higher probability of RVR/cEVR (57% vs. 32%). Among patients with LDL-C of less than 100 mg/dL, age, with an optimal cut-off of 60, was selected as the third variable of split. Younger patients had the higher probability of RVR/cEVR (49% vs. 15%). Among patients younger than 60, the blood sugar, with an optimal cut-off of 120 mg/dL, was selected as the fourth variable of split. Patients with lower blood sugar level had the higher probability of RVR/cEVR (71% vs. 31%). Among patients with hepatic steatosis of less than 30% and LDL-C of 100 mg/dL or more, age, with an optimal cut-off of 50, was selected as the third variable of split, younger being the predictor of higher RVR/cEVR probability (77% vs. 50%). Among patients older than 50,

Table 1 Clinical characteristics of patients

	Model set n = 269	Validation set n = 131	P-value
Sex (M/F)	127/142	55/76	0.325
Age (years)	57.7 ± 10.1	57.6 ± 10.0	0.932
Body weight (kg)	59.6 ± 11.0	57.5 ± 9.5	0.094
Body mass index (kg/m ²)	23.2 ± 3.1	23.3 ± 3.8	0.934
Total protein (g/dL)	7.6 ± 0.5	7.7 ± 0.6	0.558
Albumin (g/dL)	4.2 ± 0.3	4.2 ± 0.3	0.349
Globulin (g/dL)	3.4 ± 0.5	3.4 ± 0.6	0.989
Aspartate aminotransferase (IU/L)	58.1 ± 43.1	55.8 ± 37.5	0.601
Alanine aminotransferase (IU/L)	70.9 ± 49.2	66.4 ± 52.6	0.462
Gamma-glutamyltransferase (IU/L)	49.6 ± 44.0	45.2 ± 34.4	0.33
Lactate dehydrogenase (IU/L)	289.3 ± 112.3	301.5 ± 109.3	0.417
Total bilirubin (mg/dL)	0.71 ± 0.28	0.69 ± 0.23	0.317
Direct bilirubin (mg/dL)	0.23 ± 0.12	0.25 ± 0.10	0.147
Indirect bilirubin (mg/dL)	0.48 ± 0.21	0.44 ± 0.16	0.064
Alkaline phosphatase (IU/L)	290.9 ± 107.6	292.5 ± 107.6	0.917
Leucine aminopeptidase (IU/L)	64.3 ± 14.3	65.5 ± 12.3	0.543
Thymol turbidity test (KU)	7.1 ± 3.4	8.0 ± 3.7	0.062
Zinc sulfate turbidity test (KU)	15.4 ± 4.9	16.3 ± 5.4	0.188
Choline esterase (IU/L)	318.1 ± 81.7	321.1 ± 78.1	0.798
Ammonia (microg/dL)	39.7 ± 20.2	45.0 ± 15.6	0.668
Blood sugar (mg/dL)	125.9 ± 41.1	117.4 ± 47.9	0.081
Glycohemoglobin (%)	5.6 ± 1.6	5.4 ± 1.2	0.797
Total cholesterol (mg/dL)	170.8 ± 33.9	175.6 ± 36.8	0.170
Low-density-lipoprotein-cholesterol (mg/dL)	96.5 ± 25.2	100.9 ± 28.5	0.153
High-density-lipoprotein-cholesterol (mg/dL)	54.2 ± 15.9	55.2 ± 17.4	0.612
Triglyceride (mg/dL)	108.5 ± 47.8	102.8 ± 46.4	0.306
Creatinine (mg/dL)	0.72 ± 0.15	0.74 ± 0.17	0.236
Urea nitrogen (mg/dL)	14.1 ± 3.4	14.9 ± 3.9	0.123
Uric acid (mg/dL)	5.3 ± 1.2	5.2 ± 1.2	0.715
Sodium (mEq/L)	142.2 ± 2.0	142.4 ± 2.0	0.471
Potassium (mEq/L)	4.3 ± 0.3	4.3 ± 0.4	0.578
Chloride (mEq/L)	104.0 ± 2.2	104.0 ± 2.6	0.905
Calcium (mg/dL)	9.1 ± 0.4	9.2 ± 0.4	0.479
Phosphorus (mg/dL)	3.5 ± 0.5	3.5 ± 0.6	0.814
Magnesium (mg/dL)	2.2 ± 0.2	2.3 ± 0.3	0.390
Amylase (IU/L)	178.7 ± 125.8	175.1 ± 133.1	0.118
Creatine kinase (IU/L)	114.9 ± 147.6	119.3 ± 73.7	0.849
Iron (microg/dL)	104.7 ± 53.2	109 ± 37	0.726
Ferritin (ng/mL)	111.3 ± 103.3	59.7 ± 118.5	0.405
C-reactive peptide (mg/dL)	0.7 ± 1.1	0.1 ± 0.1	0.586
Immunoglobulin G (mg/dL)	1849 ± 426	1988 ± 525	0.129
Immunoglobulin M (mg/dL)	141 ± 69	205 ± 106	0.200
Immunoglobulin A (mg/dL)	323 ± 675	291 ± 81	0.784
Triiodothyronine (pg/mL)	2.3 ± 0.3	2.2 ± 0.3	0.358
Thyroxin (ng/dL)	0.9 ± 0.1	0.9 ± 0.1	0.872
Thyroid stimulating hormone (micro IU/mL)	1.8 ± 1.4	1.7 ± 0.7	0.939
White blood cell count (/microl)	5243 ± 1591	5286 ± 1101	0.843
Segmented neutrophils (%)	55.4 ± 10.8	57.0 ± 10.0	0.297
Band neutrophils (%)	1.5 ± 1.6	0.5 ± 0.6	0.250
Eosinophils (%)	2.9 ± 2.3	2.4 ± 1.4	0.127

Table 1 Continued

	Model set n = 269	Validation set n = 131	P-value
Basophiles (%)	0.6 ± 0.4	0.6 ± 0.3	0.727
Lymphocytes (%)	34.6 ± 9.6	34.0 ± 9.3	0.682
Monocytes (%)	6.6 ± 2.2	6.2 ± 2.6	0.149
Red blood cell count (10 ³ /microl)	458 ± 43	455 ± 47	0.643
Hemoglobin (g/dL)	14.4 ± 1.5	14.5 ± 1.5	0.618
Hematrit (%)	42.7 ± 4.0	42.9 ± 4.4	0.717
Reticulocytes (%)	1.4 ± 0.4	1.4 ± 0.4	0.762
Mean corpuscular volume (fl)	93.3 ± 4.5	93.8 ± 5.41	0.466
Mean corpuscular hemoglobin concentration (pg)	31.5 ± 1.9	31.7 ± 2.3	0.583
Mean corpuscular hemoglobin concentration (g/dL)	33.8 ± 0.9	33.7 ± 1.3	0.910
Platelets (10 ³ /microl)	16.8 ± 5.4	16.3 ± 4.5	0.480
Prothrombin time (s)	11.7 ± 1.2	11.7 ± 0.9	0.762
Prothrombin time (activity %)	104.6 ± 14.4	102.6 ± 14.8	0.363
Prothrombin time (international normalized ratio)	1.0 ± 0.1	1.0 ± 0.1	0.367
Thrombin time (%)	97.2 ± 31.3	109 ± 31.5	0.231
Activated partial thromboplastin time (s)	29.7 ± 4.4	29.1 ± 2.7	0.260
Hepaplastin test (%)	97.8 ± 20.3	95.4 ± 19.4	0.523
Fibrinogen (%)	237 ± 44	225 ± 45	0.069
Hepatitis C virus RNA (<850/≥850 KIU/mL)	130/139	70/61	0.394
Histological grade of			
Activity (A1/A2/A3)	138/107/24	62/55/14	0.714
Fibrosis (F1/F2/F3/F4)	135/74/57/3	58/40/27/6	0.131
Steatosis (0%/1-9%/10-29%/30%≧)	89/109/37/34	49/45/21/16	0.643
Hepatitis C virus RNA negative at week 12 (yes/no)	116/153	63/68	0.349

the level of GGT, with an optimal cutoff of 40 U/L, were then selected as the fourth level of split, low levels being the predictor of higher RVR/cEVR probability (60% vs. 35%).

All five factors selected as significant variables in the CART analysis were also significantly associated with RVR/cEVR by univariate analysis (Table 2). In addition, steatosis, LDL-C, age and GGT were also independently

Table 2 Factors associated with rapid or complete early virological response by univariate and multivariate logistic regression analysis

Parameter	Category	Univariate			Multivariate		
		Odds	95% CI	P-value	Odds	95% CI	P-value
Age (years)	<50 vs. ≥50	2.65	1.51-4.65	<0.001	2.03	1.04-3.97	0.039
Fibrosis stage	F1-2 vs. F3-4	2.47	1.31-4.66	0.005	1.77	0.85-3.68	0.120
Steatosis (%)	<30 vs. ≥30	4.11	1.64-10.29	0.003	2.88	1.07-7.79	0.037
Hepatitis C virus RNA (KIU/mL)	<850 vs. ≥850	1.97	1.21-3.22	0.007	1.93	1.09-3.43	0.025
Creatinine (mg/dL)	≥0.8 vs. <0.8	3.30	1.96-5.56	<0.001	3.54	1.88-6.67	<0.001
Hemoglobin (g/dL)	≥14.5 vs. <14.5	1.76	1.08-2.87	0.023	1.38	0.74-2.57	0.320
Hematrit (%)	≥43 vs. <43	1.75	1.07-2.84	0.003			
Gamma-glutamyltransferase (IU/L)	<40 vs. ≥40	2.06	1.26-3.37	0.004	2.45	1.32-4.56	0.005
Low-density-lipid cholesterol (mg/dL)	≥100 vs. <100	2.71	1.61-4.55	<0.001	2.21	1.21-4.06	0.010
Blood sugar (mg/dL)	<120 vs. ≥120	2.00	1.02-3.95	0.045	1.42	0.64-3.13	0.390

CI, confidence interval.




Figure 1 Classification and regression tree analysis. Boxes indicate the factors used for splitting and the cut-off value for the split. Pie charts indicate the rate of RVR/cEVR for each group of patients after splitting. Terminal subgroups of patients discriminated by the analysis are numbered from one to seven. GGT, gamma-glutamyltransferase; LDL, low-density-lipoprotein.

associated with RVR/cEVR by multivariate logistic regression analysis while blood sugar was not (Table 2). On the other hand, HCV RNA and creatinine which were significantly associated with RVR/cEVR by multivariate analysis were not selected as significant variables in CART analysis.

The probabilities of RVR/cEVR for the seven subgroups derived by this process were highly variable. The subgroup whose hepatic steatosis was less than 30%, serum LDL-C was 100 mg/dL or more and of an age less than 50 years (subgroup 7) showed the highest probability of RVR/cEVR (77%), while the subgroup whose hepatic steatosis more than 30% (subgroup 1) and the subgroup whose hepatic steatosis was less than 30% but serum LDL-C was less than 100 mg/dL and of an age

greater than 60 years (subgroup 2) showed the lowest probability of RVR/cEVR (18% and 15%, respectively).

Validation of the CART analysis

The results of the CART analysis were validated with a validation dataset of 131 cases which is independent of the model building dataset. Each patient in the validation set was allocated to subgroups 1-7 using the flow-chart form of the CART tree. The rates of RVR/cEVR were 20% for subgroups 1 and 2, 29% for subgroups 3, 38% for subgroup 4, 59% for subgroup 5, 71% for subgroup 6, and 85% for subgroups 7. The rates of RVR/cEVR for each subgroup of patients were closely correlated between the model building dataset and the validation dataset (Fig. 2).




Figure 2 Validation of the classification and regression tree (CART) analysis: Subgroup stratified comparison of the rate of rapid or complete early virological response (RVR/cEVR) between the model building and validation datasets. Each patient in the validation set was allocated to subgroups 1–7 by following the flow-chart form of the CART tree and the rates of RVR/cEVR were calculated. The rate of RVR/cEVR in each subgroup was plotted. The x-axis represents the rate of RVR/cEVR in the model building datasets and the y-axis represents the rate of RVR/cEVR in the validation datasets. The rates of achieving RVR/cEVR in each subgroup of patients closely correlated between the model building dataset and the validation dataset ($r^2 = 0.987$).

Construction of 3 groups according to the probability of RVR/cEVR

If the seven subgroups were reconstructed into three groups according to their rate of RVR/cEVR, the rate of RVR/cEVR was 16% for low probability group (subgroup 1 and 2), 46% for intermediate probability group (subgroup 3, 4, and 5) and 75% for high probability group (subgroup 6 and 7; $P < 0.0001$).

Effect of adherence

Adherence of PEG-IFN and RBV was not included as a variable of analysis since the present study aimed to develop a pre-treatment model for the prediction of response. To analyze the possible effect of adherence on the result of CART analysis, three groups of patients divided by CART (low, intermediate and high probability group) were further stratified according to adherence

of PEG-IFN and RBV. Poor adherence was defined as taking less than 80% planned dose of PEG-IFN or RBV at 12 weeks, and good adherence was defined as taking more than 80% planned dose of both PEG-IFN and RBV at 12 weeks. The result is shown in Figure 3. Among patients with good adherence, the rate of RVR/cEVR was 19% for low probability group, 52% for intermediate probability group and 77% for high probability group. Among poor adherence group, the rate of RVR/cEVR was 13% for low probability group, 41% for intermediate probability group and 73% for high probability group. Collectively, even after adjustment for adherence, 3 groups of patients divided by CART analysis still had low, intermediate and high probability of achieving RVR/cEVR, respectively.

DISCUSSION

IN THE PRESENT study, we performed the CART analysis and built a simple decision tree model for the pre-treatment prediction of response to PEG-IFN plus




Figure 3 The rate of rapid or complete early virological response (RVR/cEVR) between the classification and regression tree (CART) groups stratified by adherence. The three groups of patients divided by CART (low, intermediate and high probability group) were further stratified according to adherence of peg-interferon (PEG-IFN) plus ribavirin (RBV). Black, white and gray boxes in the bar chart indicate total patients, patients with poor adherence (taking less than 80% planned dose of PEG-IFN or RBV at 12 weeks), and good adherence (taking more than 80% planned dose of both PEG-IFN and RBV at 12 weeks), respectively. Even after adjustment for adherence, 3 groups of patients divided by CART analysis still had low, intermediate and high probability of achieving RVR/cEVR, respectively.

RBV therapy. The analysis highlighted five host variables relevant to response: steatosis, LDL-C, age, blood sugar and GGT. Classification of patients based on these variables identified subgroups of patients with high probabilities of achieving RVR/cEVR among difficult to treat chronic hepatitis C patients. The reproducibility of the model was confirmed by the independent validation datasets. According to the result of the CART, patients were categorized into 3 groups: the rate of RVR/cEVR was 16% for low probability group, 46% for intermediate probability group and 75% for high probability group. The result of the CART analysis could be readily applicable to clinical practice because patients could be allocated to specific subgroups with a defined rate of response simply by following the flow-chart form. Although an early disappearance of serum HCV RNA is the prerequisite for achieving SVR, no reliable baseline predictors of response to PEG-IFN plus RBV therapy are established to date. Thus, this model may have the potential to support decisions in patient selection for PEG-IFN plus RBV therapy or to tailor treatment strategies for individual patients. Moreover, our result may provide a rationale for treating metabolic factors to improve the efficacy of antiviral therapy.

Among variables relevant to the prediction of RVR/cEVR, the grade of hepatic steatosis was selected as the variable of the first split. Previous studies suggested that steatosis induces resistance to IFN and RBV combination therapy^{20,21} along with underlying metabolic factors such as insulin resistance or obesity.²¹⁻²⁴ In the present study, the grade of steatosis correlated positively with BMI and serum glucose level (data not shown) suggesting the etiologic role of metabolic factors. In addition, serum glucose level was selected as a predictor of RVR/cEVR at the fourth level of split. Serum GGT, which is associated with obesity,²⁵ insulin resistance²⁶ and response to IFN therapy,²⁷⁻²⁹ was also selected as a predictor of RVR/cEVR at fourth level of splitting which may emphasize the importance of metabolic factors in therapeutic resistance. These findings raise the possibility that treatment of these metabolic factors may improve the virological response to the PEG-IFN plus RBV therapy. This hypothesis should be examined by a prospective study.

We and others have reported that steatosis, obesity and insulin resistance are associated with the progression of fibrosis,^{17,31-33} which can interfere indirectly with the effect of IFN on hepatocytes. Other possible mechanisms of resistance by steatosis or metabolic factors include dysregulation of adipocytokines³⁴ or oxidative stress which may inhibit intracellular IFN signaling

pathway.³⁵ Despite these findings, the precise mechanism of resistance is not established and further investigation is needed.

Another factor relevant in the prediction of RVR/cEVR was LDL-C. LDL-C was selected as the second factor for splitting by CART, and was an independent predictor of RVR/cEVR by logistic regression analysis. LDL-C recently has attracted attention as a novel predictor of response to IFN or PEG-IFN plus RBV.^{34,36,37} Since *in vitro* study showed that LDL-C receptor acts as a receptor for HCV and LDL-C competitively inhibit the binding of HCV,³⁸ high level of serum LDL-C may inhibit HCV entry to hepatocytes and attenuate replication. LDL-C and its receptor may be a future therapeutic target.

Not all factors selected as significant variables in the CART analysis were also significantly associated with response by standard statistical analysis: blood sugar was associated with response by univariate analysis but not by multivariate logistic regression analysis. On the other hand, HCV RNA and creatinine which were significantly associated with RVR/cEVR by multivariate analysis were not selected as significant variables in CART analysis. These differences may indicate both the unique feature and the limitations of the CART analysis. To note, blood sugar was significantly associated with RVR/cEVR within specialized subgroups of patients defined by the CART analysis: in subgroup of patients with steatosis <30%, LDL-C <100 mg/dl, and younger than 60, which indicate the unique feature of the CART analysis that it could visualize significant predictors that specifically apply to selected patients. The limitation is that not all significant factors may be adopted in the decision tree since we applied the rule to stop CART procedure when the sample size was below 20. This rule was applied to avoid the generation of over-fit model which may lack universality. Therefore, it is possible that HCV RNA or creatinine may become a significant variable in the CART analysis if larger number of patients were included in the analysis. Stage of fibrosis was significantly associated with response to therapy by univariate analysis but not by multivariate analysis and not selected as a significant variable in the CART analysis. The possible reason is that advanced fibrosis is associated with older age as a confounding factor.

CART analyses are gaining acceptance in medical research in addition to biomedical field. Recent publications include the prediction of aggressive prostate cancer,⁸ diabetic vascular complications,¹² prognosis of melanoma,^{2,39} response to preoperative radiotherapy for rectal tumor,⁹ prognostic groups in colorectal carcinoma,¹⁷ and outcome after liver failure.¹¹ An advantage

of CART over traditional regression models is that it can identify prognostic subgroups that are useful in clinical practice. Because the results of CART analysis are presented as a decision tree, which is intuitive, they can be readily interpreted by medical professionals without any specific knowledge of statistics. The most important consideration is that five variables used in the decision tree were clinical parameters that are readily available by the usual work-up of patients before therapy. Especially, glucose, GGT and LDL-C are simple biochemical markers that are easily measured at a low cost. Using this model, we can rapidly develop an estimate of the response before treatment, which may facilitate clinical decision making.

In conclusion, we built a pre-treatment model for the prediction of virological response in PEG-IFN plus RBV therapy. Because this decision tree model was made up of simple host factors such as steatosis, LDL-C, age, blood sugar and GGT, it can be easily applied to clinical practice. This model may have the potential to support decisions in patient selection for PEG-IFN plus RBV therapy based on the possibility of response against a potential risk of adverse events or costs, and may provide a rationale for treating metabolic factors to improve the efficacy of antiviral therapy.

ACKNOWLEDGEMENTS

THIS STUDY WAS supported by a grant-in-aid from Ministry of Health, Labor and Welfare, Japan. There exist no conflicts of interest.

REFERENCES

- Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004; 39: 1147-71.
- Fried MW, Shiffman ML, Reddy KR *et al*. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975-82.
- Manns MP, McHutchison JG, Gordon SC *et al*. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958-65.
- Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey I, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 2003; 38: 645-52.
- Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. *Antivir Ther* 2008; 13 (Suppl 1): 9-16.
- Breiman L, Friedman RA, Olshen CJ, Stone CM. *Classification and Regression Trees*. Calif: Wadsworth, 1980.
- Averbook BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. *Surg* 2002; 132: 589-602.
- Garzotto M, Beer TM, Hudson RG *et al*. Improved detection of prostate cancer using classification and regression tree analysis. *J Clin Oncol* 2005; 23: 4322-9.
- Zlobec I, Steele R, Nigam N, Compton CC. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. *Clin Cancer Res* 2005; 11: 5440-3.
- Jin H, Lu Y, Harris SF *et al*. Classification algorithms for hip fracture prediction based on recursive partitioning methods. *Med Decis Making* 2004; 24: 386-98.
- Baquerizo A, Anselmo D, Shaddeton C *et al*. Phosphorus as an early predictive factor in patients with acute liver failure. *Transplantation* 2003; 75: 2007-14.
- Valera VA, Walter BA, Yokoyama N *et al*. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. *Ann Surg Oncol* 2007; 14: 34-40.
- Martin MA, Mcynick R, O'Neill T, Roberts S. Mastectomy or breast conserving surgery? Factors affecting type of surgical treatment for breast cancer - a classification tree approach. *BMC Cancer* 2006; 6: 98.
- LeBlanc M, Crowley J. A review of tree-based prognostic models. *Cancer Treat Res* 1995; 75: 113-24.
- Costanza MC, Paccaud F. Binary classification of dyslipidemia from the waist-to-hip ratio and body mass index: a comparison of linear, logistic, and CART models. *BMC Med Res Methodol* 2004; 4: 7.
- Bedossa P, Poinard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996; 24: 289-93.
- Kurosaki M, Matsunaga K, Hirayama I *et al*. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. *J Hepatol* 2008; 48: 736-42.
- Segal MR, Bloch DA. A comparison of estimated proportional hazards models and regression trees. *Stat Med* 1989; 8: 539-50.
- Miyaki K, Takei I, Watanabe K, Nakashima H, Omae K. Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. *J Epidemiol* 2002; 12: 243-8.
- Akuta N, Suzuki E, Tsubota A *et al*. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. *J Hepatol* 2002; 37: 831-6.

- 21 Poynard T, Ratzin V, McHutchison J *et al.* Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology* 2003; 38: 75-85.
- 22 Bressler BL, Cuindi M, Tomlinson C, Heathcote J. High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C. *Hepatology* 2003; 38: 639-44.
- 23 Romero-Gomez M, Del Mar Vitoria M, Andrade RJ *et al.* Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology* 2005; 128: 636-41.
- 24 Konishi I, Horiike N, Hiasa Y *et al.* Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. *Hepatol Res* 2007; 37: 331-6.
- 25 Marchesini G, Avagnina S, Barantani EG *et al.* Aminotransferase and gamma-glutamyltransferase levels in obesity are associated with insulin resistance and the metabolic syndrome. *J Endocrinol Invest* 2005; 28: 333-9.
- 26 Fraser A, Ebrahim S, Smith GD, Lawlor DA. A comparison of associations of alanine aminotransferase and gamma-glutamyltransferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. *Hepatology* 2007; 46: 158-65.
- 27 Mazzella G, Salzetta A, Casanova S *et al.* Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. *Dig Dis Sci* 1994; 39: 866-70.
- 28 Villela-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. *J Clin Gastroenterol* 2005; 39: 728-30.
- 29 Berg T, Sarrazin C, Herrmann E *et al.* Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology* 2003; 37: 600-9.
- 30 Akuta N, Suzuki F, Kawamura Y *et al.* Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 2007; 46: 403-10.
- 31 Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Uthi R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 2001; 33: 1358-64.
- 32 Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. *Am J Gastroenterol* 2002; 97: 2408-14.
- 33 Muzzi A, Leandro G, Rubbia-Brandt L *et al.* Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. *J Hepatol* 2005; 42: 41-6.
- 34 Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. *Hepatology* 2006; 43: 1177-86.
- 35 Di Bona D, Cippitelli M, Fionda C *et al.* Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. *J Hepatol* 2006; 45: 271-9.
- 36 Minuk GY, Weinstein S, Kaita KD. Serum cholesterol and low-density lipoprotein cholesterol levels as predictors of response to interferon therapy for chronic hepatitis C. *Ann Intern Med* 2000; 132: 761-2.
- 37 Gopal K, Johnson TC, Gopal S *et al.* Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. *Hepatology* 2006; 44: 335-40.
- 38 Agnello V, Abel G, Elfahal M, Knight CB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc Natl Acad Sci USA* 1999; 96: 12766-71.
- 39 Leiter U, Buettner PG, Figentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German dermatological society. *J Clin Oncol* 2004; 22: 3660-7.

HCV Genetic Elements Determining the Early Response to Peginterferon and Ribavirin Therapy

Nobuyuki Enomoto Shinya Maekawa

First Department of Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Japan

© S. Karger AG, Basel
**PROOF Copy
for personal
use only**
ANY DISTRIBUTION OF THIS
ARTICLE WITHOUT WRITTEN
CONSENT FROM S. KARGER
AG, BASEL IS A VIOLATION
OF THE COPYRIGHT.

Key Words

Full open reading frame analysis · Hepatitis C virus · Peginterferon/ribavirin therapy

Abstract

The aim of this study was to search hepatitis C virus (HCV) genetic elements determining the early response to peginterferon/ribavirin therapy using HCV genome-wide analysis. From a total of 88 chronic hepatitis C patients with HCV-1b treated with peginterferon/ribavirin, the whole HCV amino acid sequence was determined and analyzed according to the viral response during the treatment. Mutations in NS5A-ISDR (interferon sensitivity-determining region) are associated with rapid viral response at week 4, and the core arginine70glutamine (R70Q) mutation is associated with no early viral response at week 12, revealing that core 70 and NS5A are the most important factors determining the virological kinetics during peginterferon and ribavirin therapy.

Copyright © 2010 S. Karger AG, Basel

Introduction

Hepatitis C virus (HCV) is a major cause of chronic liver diseases, and worldwide 170 million people are infected with HCV. With the introduction of the recent

combination therapy of pegylated-interferon (PEG-IFN) and ribavirin (RBV), half of patients can eradicate the virus (sustained virological response, SVR). The SVR rate of HCV to the PEG-IFN/RBV therapy is dependent on HCV genotypes, and the viral kinetics during the treatment strongly affect the final viral clearance [1, 2]. It is generally considered that HCV structures affect the treatment response since the SVR rate to PEG-IFN/RBV therapy depends upon viral genotypes as described above. However, comprehensive analysis of the contribution of HCV structures to different responses has not yet been conducted. In the present study, in order to clarify the relationship between HCV sequences and viral responses, we have determined the complete HCV open reading frame sequences obtained from pretreatment patients' serum, and investigated their response by searching for HCV genetic elements determining the early response to PEG-IFN/RBV therapy using HCV genome-wide analysis.

Methods

A total of 88 chronic hepatitis C patients with HCV-1b treated with PEG-IFN/RBV were studied. From pretreatment sera, the whole HCV deduced amino acid sequence (3,010 amino acids) was determined in each patient by direct RT-PCR.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2010 S. Karger AG, Basel
0300-5526/10/0531-0066\$26.00/0

Accessible online at:
www.karger.com/int

Nobuyuki Enomoto, MD
First Department of Medicine, Faculty of Medicine
University of Yamanashi
1110 Shimokato, Chuo, Yamanashi 409-3898 (Japan)
Tel. +81 55 273 9584, Fax +81 55 273 6748, E-Mail enomoto@yamanashi.ac.jp




Fig. 1. Reciprocal of p value for sliding window analysis with 77 amino acid width for RVR versus others.

Amino acid usage of each of the 3,010 positions was compared according to the different virological response in order to identify the single amino acid differences determining the virological response. In addition, sliding window analyses were carried out in order to identify the amino acid region associated with the virological response. The number of the amino acid changes in the fixed stretch of the sequence (window: 2–100 amino acids) were compared according to the virological response, scanning the whole HCV amino acid sequence by sliding this window one by one.

Results

Of 88 patients studied, 9 showed rapid viral response (RVR; HCV-RNA undetectable at week 4) and 71 showed early viral response (EVR; over 2-log drop of HCV-RNA at week 12). The other 17 patients showed no EVR, indicating these patients are highly resistant to the treatment.

Mutations in the region overlapping NS5A-ISDR (interferon sensitivity-determining region, aa2209–2248) are associated with the good response to PEG-IFN/RBV therapy as shown in sliding window analysis comparing RVR patients at week 4 and others (fig. 1). In contrast, the core R(arginine)70Q (glutamine) mutation is associated with a poor response resulting in no EVR at week 12 by single amino difference analysis comparing non-EVR patients and the others (fig. 2).

Discussion

In the present study, using a sliding window analysis comparing all HCV amino acids, the amino acid region located in ISDR was extracted as the most significant region discriminating the RVR and non-RVR patients. By




Fig. 2. Reciprocal of p value for single amino acid difference along the whole HCV sequence for non-EVR versus others.

comparing amino acids between the non-EVR patients and the others, remarkable differences were clustered in a single amino acid polymorphism in the core 70. Recent studies have proven that the initial viral response at week 4 and week 12 of the PEG-IFN/RBV therapy could be a useful predictor of the final outcome, indicating that the present findings are important for predicting treatment outcome and individualizing the treatment regimen for each patient as well as understanding the mechanism of diverse response to PEG-IFN/RBV therapy.

ISDR was first identified as the region significantly related to SVR in the era of IFN monotherapy in Japanese patients [3, 4]. 'Mutant type', meaning 4 or more mutations in the region, was associated with high SVR rate, while the rate was low in the 'intermediate type' (1–3 mutations) and wild type (no mutation). Though there were controversies as to the predictive value of ISDR, since studies in Europe and in North America did not necessarily reproduce evident correlation between ISDR and SVR, a recent meta-analysis proved its value by demonstrating a clear relationship all over the world, even in Western countries [5]. The present study reproduced the significance of ISDR in PEG-IFN/RBV therapy. Mutations in ISDR make HCV highly sensitive to IFN, leading to RVR. Current guidelines indicate that RVR patients with low viral load before treatment can be treated with 24 weeks instead of the standard 48 weeks of therapy. Since most ISDR mutant patients show low viral loads, these easy-to-treat patients in genotype 1b should be mainly infected with HCV with ISDR mutations, suggesting ISDR genotyping would identify the patients treatable with the abbreviated regimen.

On the other hand, in the present study, the polymorphism of core 70 was extracted as the most significant position to determine poor virological response in 12 weeks (non-EVR). The contribution of core region amino acid polymorphism in resistance to (PEG-)IFN/RBV therapy was previously reported by Akuta et al. [6], who first found that the polymorphisms in a combination of core 70 and 91 were closely related to the final outcome. The importance of core 70 polymorphism alone, however, was considered rather weak in their study for its smaller p value. Their end point was the final outcome of the treatment, which could be influenced by a variety of factors other than viral genetics, such as host factors (age, sex, fibrosis, body weight, etc.) and treatment (dose of